⌕
Cellebrite DI · CLBT · Nasdaq
Tenet 62 · Solid
Compare
$11.12−3.56%At closeTenet 62 · Solid
$11.12−0.41 (−3.56%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Cellebrite DI (CLBT) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~17.9%/yr (FY21→FY25), net margin 16.5%, and free cash flow (~$160.3M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+54.7%) and Capex step-up ($13.2M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲18.6%
475.7
FY21→FY25CAGR +17.9%/yr
Net income ($M)—
78.3
one-off year: see footnoteCAGR +2.3%/yr
Free cash flow ($M)▲29.7%
160.3
capex stepped upCAGR +50.9%/yr
Diluted EPS—
0.31
FY21→FY25CAGR −8.4%/yr
What the receipts whisper · what a headline number hides
Share count
+54.7%

161.5mn → 249.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$13.2M

▲54% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)475.7Revenue−75.2COGS400.5Gross profit−113.9R&D−65.3SG&A66.5Op income11.8Tax & other78.3Net income

16¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~10%FY21FY25

Over this window: gross 82.7% → 84.2%. Net margin 16.5% is above the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
475,675.0475,675.0401,203.0325,110.0270,651.0246,246.0▲18.6%+17.9%
Cost of revenue
75,172.075,172.062,593.053,231.050,746.042,557.0▲20.1%+15.3%
Gross profit
400,503.0400,503.0338,610.0271,879.0219,905.0203,689.0▲18.3%+18.4%
Research & development
113,877.0113,877.098,415.084,386.080,620.065,541.0▲15.7%+14.8%
Selling, general & admin
65,332.065,332.050,900.043,443.040,854.047,937.0▲28.4%+8.0%
Total operating expenses
334,023.0334,023.0281,704.0238,642.0218,861.0189,867.0▲18.6%+15.2%
Operating incomefeeds ROC rank
66,480.066,480.056,906.033,237.01,044.013,822.0▲16.8%+48.1%
Other income, net
24,198.024,198.0−332,890.0−108,800.0119,716.068,483.0——
Pretax income
90,678.090,678.0−275,984.0−75,563.0120,760.082,305.0—+2.5%
Income tax
12,352.012,352.07,023.05,537.0−45.010,909.0▲75.9%+3.2%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
78,326.078,326.0−283,007.0−81,100.0120,805.071,396.0—+2.3%
Per share
Diluted EPSbuyback-sensitive
0.310.31−1.35−0.430.590.44—−8.4%
Diluted shares (mn)
249.90249.90209.47190.15195.39161.54▲19.3%+11.5%
Margins
Gross margin94th pct in Technology
84.2%84.2%84.4%83.6%81.3%82.7%▼0.2pp+1.5pp
Operating margin
14.0%14.0%14.2%10.2%0.4%5.6%▼0.2pp+8.4pp
Net margin69th pct in Technology
16.5%16.5%−70.5%−24.9%44.6%29.0%▲87.0pp−12.5pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.FY21 effective tax rate was 13% vs a −0% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 14% vs a −0% norm for this window, likely a one-time item; see the filing.
FY19 – FY20 · 2 more years
Unlock the full history →
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-03 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Cellebrite DI's revenue last fiscal year?

Cellebrite DI reported revenue of $475.7M in fiscal 2025, up 18.6% from fiscal 2024.

What was Cellebrite DI's net income?

Cellebrite DI reported net income of $78.3M in fiscal 2025, a net margin of 16.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.